Stronger Exelon Patch Wins FDA Nod

A transdermal patch delivering rivastigmine (Exelon) at a 40 percent higher rate than the previous maximum strength has been cleared by the FDA for patients with mild to moderate Alzheimer's disease, its manufacturer said.
MedPage Today